
            Rhodiola crenulata extract counteracts the effect of hypobaric hypoxia in rat heart via redirection of the nitric oxide and arginase 1 pathway by Shih-Wei Hsu et al.
RESEARCH ARTICLE Open Access
Rhodiola crenulata extract counteracts the
effect of hypobaric hypoxia in rat heart via
redirection of the nitric oxide and arginase
1 pathway
Shih-Wei Hsu1, Tsu-Chung Chang2, Yu-Kuan Wu2, Kuen-Tze Lin3, Li-Shian Shi4 and Shih-Yu Lee5*
Abstract
Background: Rhodiola crenulata is traditionally used as a folk medicine in Tibet for preventing high-altitude illnesses,
including sudden cardiac death (SCD). The cardio-protective effects of Rhodiola crenulata root extract (RCE) against
hypoxia in vivo have been recently confirmed. However, the way in which RCE produces these effects remains unclear.
The present study is designed to confirm the protective effects of RCE on the heart in acute hypobaric hypoxia
exposure and examine the mechanisms by which this occurs.
Methods: Sprague–Dawley (SD) rats were pretreated with or without RCE and then exposed to a simulated altitude of
8000 m in a hypobaric hypoxia chamber for 9 h. The expression of cardiac arginase 1 (Arg-1) and endothelial nitric oxide
synthase (eNOS) and the activity of associated signaling pathways was examined.
Results: Hypoxia reduced cardiac eNOS phosphorylation and increased Arg-1 expression, but both responses
were reversed by RCE pre-treatment. In addition, RCE decreased the hypoxia-induced oxidative stress markers of
reactive oxygen species (ROS) production, malondialdehyde (MDA) level, and protein carbonyl content. Furthermore,
RCE protected cardiomyocytes from hypoxia-induced cardiac apoptosis and restored the phosphorylation level of AKT
and p38 MAPK as well as the superoxide dismutase 2 (SOD2) content in hypoxic animals.
Conclusion: The findings provide evidence that the effects of Rhodiola crenulata against altitude illness are partially
mediated by modulation of eNOS and Arg-1 pathways in the heart.
Keywords: Rhodiola crenulata, Hypobaric hypoxia, Heart, Nitric oxide, Arginase 1
Background
Acute exposure to high altitude involves a hypobaric hyp-
oxic environment. This may initiate pulmonary arterial
vasoconstriction, increased vascular resistance, pulmonary
hypertension, and high-altitude pulmonary edema (HAPE)
in individuals. These events may even have lethal conse-
quences [1]. In addition to the pulmonary alterations, sud-
den cardiac death (SCD) is another common cause of
death that is associated with vasoconstriction and pulmon-
ary hypertension and even more rapid lethality during
high-altitude activities [2]. Hypobaric hypoxia is considered
as a cardiac stressor and may lead to some cardiovas-
cular disorders such as myocardial infarction (MI)
and pulmonary hypertension-induced right ventricular
(RV) dysfunction [3]. In individuals with heart dis-
ease, hypoxic conditions also decrease the ischemic
threshold and increase the arrhythmia frequency [2].
Thus, the impact of hypobaric hypoxia on the heart
has been a focus of investigation in recent years.
Nitric oxide (NO), a crucial regulator of vascular tone
and blood pressure, is regarded as a cardiac protector
[4]. Many hypoxia-induced disorders, including endothe-
lial dysfunction, pulmonary artery vasoconstriction, and
pulmonary hypertension (PH) are highly associated with
impairment of the endothelial nitric-oxide synthase
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(eNOS) pathway and NO production [5, 6], especially in
individuals who are prone to high-altitude illness [7].
Arginase, an important enzyme in the urea cycle, has
been reported to be involved in many cardiovascular dis-
orders such as PH, atherosclerosis, MI, and congestive
heart failure [8]. Once activated, arginase competes with
eNOS and reacts with L-arginine, resulting in reduced
NO availability. Thus, arginase plays a crucial role in
adaptation to hypoxia [9]. Reactive oxygen species (ROS)
are also associated with pulmonary artery vasoconstric-
tion and offsetting of NO signaling [10]. The hypoxia-
induced ROS burst in the heart causes oxidative damage
to biomolecules (DNA, proteins, and lipids), which may
depress myocardial contraction and dysfunction [11].
Rhodiola crenulata, a popular folk medicine for anti-
altitude sickness in Tibet [12], has been recently re-
ported as having cardio-protective effects on hypoxia in
vivo [13, 14] and in rodent models of acute exhaustive
injury [15]. However, the detailed mechanisms by which
RCE protects against hypoxia remain unclear. We have
previously shown that RCE alleviates hypoxia-induced
pulmonary edema in rats [16]. This effect was mediated
via a decrease in the level of endothelin-1 (ET-1), a nat-
ural counterpart of NO in vascular function. In the
present study, we have investigated whether RCE exerts
cardio-protective effects against hypobaric hypoxic con-
ditions via redirection of the NO and arginase 1 (Arg-1)
pathway.
Methods
Preparation and Quality Control of RCE
Preparation and analysis of RCE were described in a previ-
ous study by our group [17]. Briefly, Rhodiola crenulata
(Hook. f. & Thomson) H. Ohba roots were obtained from
Chuang Song Zong Pharmaceutical Co., Ltd (Kaohsiung,
Taiwan). A voucher specimen (NDMCP no.1000901) was
deposited in the National Defense Medical Center. The
identity of R. crenulata was confirmed using the Plant List
database. 2.0 kg dry powder was extracted with 95% ethanol
and then yielded 320.24 g RCE after condensation under
reduced pressure. The drug-extract ratio was 6.25:1. To
identify the content of bioactive marker salidroside in RCE,
HPLC was conducted. The 10.0 mg of RCE dissolved in
1 ml of methanol was analyzed by HPLC with a Lichro
CARTR RP-18e (4.0 mm× 250 mm i.d., 5 μm; Merck,
Germany) column. The samples were eluted with a H2O-
acetonitrile gradient system for 60 min at a flow rate of
1.0 ml/min. The analytes were quantified with a wavelength
of 223 nm. The calibration curve was linear within a range
of 0.125–1.0 mg/ml (R2 = 0.9927); the average recovery
using this method (n = 3) was 98.9%, the RSD (n = 3) was
2.9%, and RPD was 2.2%. HPLC showed that the RCE con-
tained 3.5% salidroside (Additional file 1).
Hypobaric Hypoxia Exposure
The method was as described previously [16]. Briefly, the
male Sprague–Dawley rats (4–6 weeks old; weighing 150–
180 g) were unexposed to hypoxia (control) or exposed to
50 mg/kg RCE alone. The conditions for animal exposure
to hypoxia involved a simulated altitude of 8000 m for 9 h.
Hypoxia-exposed rats were fed 0 (control), 50, or 100 mg/
kg RCE by gavage for three days before the exposure to
hypobaric hypoxia. Afterwards, rats were anesthetized and
blood samples were taken from the right ventricles. Finally,
the hearts were dissected and stored at −80 °C until use.
All of these procedures were performed according to the
Institutional Animal Care and Use Committee of the
National Defense Medical Center (IACUC-15-122).
Griess Assay
Nitrite, the breakdown product of NO, was measured
using a nitrite colorimetric assay kit purchased from
Cayman Chemicals (MI, USA) [11]. In brief, 20 mg
sample was homogenized in 120 μl of assay buffer and
then centrifuged at 10000 g for 5 min. Supernatant
(100 μl) was reacted with Griess solution (100 μl) for
10 min. The absorbance was measured at 570 nm in an
EIA Reader (Molecular Devices, Sunnyvale, CA, USA).
Measurement of cGMP and Protein Carbonyl Content
Measurements of cGMP and protein carbonyl content were
performed using commercial kits from Cayman Chemicals
(MI, USA). Briefly, 20 mg of heart tissue were homogenized
in 120 μl of 0.1 N HCl for cGMP and 40 mg of heart tissue
was homogenized in 200 μl of PBS for protein carbonyl.
Afterwards, the samples were centrifuged at 1000 g for
5 min. Subsequently, the supernatant was collected and
measurements performed according to the manufacturer’s
instructions.
Arginase activity
Arginase activity was evaluated using a commercial kit
(Abnova Corp., Taiwan) [18]. Briefly, heart tissue was
homogenized and centrifuged at 10000 g for 5 min. The
supernatant was reacted with reaction solution and the
absorbance was measured at 570 nm.
ROS level
The assay was performed as in our previous study [16].
Briefly, heart tissue was homogenized in RIPA lysis buf-
fer and then centrifuged at 10000 g for 5 min. Super-
natant (20 μl) was reacted with 20 mM DCFH-DA (2,7,
dichlorofluorescein diacetate) in PBS at 37 °C for
15 min. The excitation wavelength was 485 nm and the
emission wavelength was 538 nm.
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Western Blot Analysis
The expression of proteins in heart tissues was quanti-
fied as described previously [17]. Primary antibodies
used from Cell Signaling Tech (Danvers, MA, USA)
were phosphorylated eNOS (p-eNOS), Arg-1, Bcl-XL,
p38 MAPK, phosphorylated p38MAPK (p-p38 MAPK),
extracellular signal-regulated kinase 1/2 (ERK1/2), and
phosphorylated ERK1/2 (p-ERK1/2). Primary antibodies
for caspase-3, Bax, and Bcl2 were obtained from Gene-
Tex (San Antonio, TX, USA). Antibodies for superoxide
dismutase 1 (SOD1), SOD2, glutathione peroxidase 2
(GPx2), AKT, p-AKT (Thr308), p-AKT (Ser473), and
eNOS were obtained from Santa Cruz (CA, USA), and
antibodies for β -actin were obtained from Chemicon
(Temecula, CA, USA).
Statistical analysis
All results are presented as mean ± SEM. Significant
differences between group means were determined
using one-way ANOVA followed by Bonferroni’s post-
hoc test. Analyses were performed using IBM SPSS
Statistics version 22 (IBM® SPSS® Statistics 22). Differ-
ences were considered to be statistically significant
when p-values were less than 0.05.
Results
RCE decreased the expression and activity of Arg-1 induced
by hypobaric hypoxia
The expression of cardiac Arg-1 under conditions of
hypobaric hypoxia was examined by western blotting.
Hypoxia significantly (p < 0.05) increased the Arg-1 pro-
tein level (1.25 ± 0.01-fold over control, Fig. 1a and b).
Hypoxia also significantly (p < 0.01) increased arginase
activity from 0.26 ± 0.02 nmol/min/μl in the control
group to 0.49 ± 0.01 nmol/min/μl (Fig. 1c). These results
indicate that hypoxia increases both Arg-1 expression
and arginase activity in heart tissue. However, treatment
with RCE significantly suppressed hypoxia-induced Arg-
1 expression (1.03 ± 0.05-fold over control for 50 mg/kg
of RCE [p < 0.05] and 0.98 ± 0.01-fold over control for
100 mg/kg of RCE [p < 0.05]) (Fig. 1a and b). Arginase
activity was significantly (p < 0.05) suppressed at 0.35 ±
0.03 nmol/mg protein/min for 50 mg/kg of RCE and
0.37 ± 0.02 nmol/mg protein/min for 100 mg/kg of RCE,
p < 0.05, respectively. These findings indicated that RCE
treatment diminished both hypoxia-induced Arg-1 ex-
pression and activity in rat heart.
RCE restored NO metabolism and signaling suppressed
by hypobaric hypoxia
The effect of RCE on NO metabolism and eNOS expres-
sion was investigated. As shown in Fig. 2a and b, hypoxia
significantly suppressed the phosphorylation of eNOS at
Ser1177 (0.55 ± 0.11-fold of control at p < 0.05). However,
RCE treatment restored the p-eNOS level under hypoxic
conditions (0.96 ± 0.08 over the control for 50 mg/kg of
RCE and 1.06 ± 0.16-fold over the control for 100 mg/kg of
RCE at p < 0.05). RCE treatment also significantly increased
the levels of eNOS under both normal conditions (1.21 ±
0.04-fold of control at p < 0.01) and hypoxic conditions
(1.12 ± 0.10 over the control for 50 mg/kg of RCE and
1.14 ± 0.03-fold over the control for 100 mg/kg of RCE at
p < 0.05, Fig. 2c).
In addition, RCE administration increased the nitrite
content in the heart homogenate from 2.07 ± 0.04 μM up
to 2.47 ± 0.07 μM for 50 mg/kg of RCE and up to 2.51 ±
0.08 μM for 100 mg/kg of RCE at p < 0.01, respectively
(Fig. 2d). Similarly, the level of cGMP, a putative down-
stream product of NO, was also restored by RCE treatment
from 4.89 ± 0.02 nmol/mg protein to 6.64 ± 0.13 nmol/mg
protein for 50 mg/kg of RCE (p < 0.01) and up to 7.13 ±
0.10 nmol/mg protein for 100 mg/kg of RCE (p < 0.001)
Fig. 1 Effect of RCE on cardiac arginase expression and activity. After
hypobaric hypoxia exposure (8000 m) for 9 h, the expression level of
Arg-1 and arginase activity were analyzed by western blotting (a) and a
commercial kit (b), respectively. A quantitative analysis of the Arg-1
expression level was conducted (c). The results represent the mean ±
SEM (n = 3). *p < 0.05 and **p < 0.01 vs. the sample without RCE.
#p < 0.05 and ##p < 0.01 versus hypoxia (H)
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(Fig. 2e). Based on these findings, we inferred that RCE
treatment restores the hypoxia-impaired NO bioavailability
and signaling in heart tissues.
RCE eliminated the hypobaric hypoxia-induced cardiac
oxidative stress
In order to examine the effect of RCE on hypoxia-induced
cardiac oxidative stress, the levels of ROS, MDA, and pro-
tein carbonyl in the heart tissues were measured. As shown
in Fig. 3a, b, and c, hypobaric hypoxia significantly
increased ROS generation (1.24 ± 0.05-fold over control at
p < 0.05), MDA (from 1.26 ± 0.01 nmol/mg protein for the
control to 3.25 ± 0.52 nmol/mg protein at p < 0.05), and
protein carbonyl (from 2.27 ± 0.11 nmol/mg protein of the
control to 3.30 ± 0.30 nmol/mg protein at p < 0.05) levels in
hypoxic heart tissues. However, RCE treatment significantly
lowered the hypoxia-induced ROS burst to 0.98 ± 0.03-fold
over control for 50 mg/kg of RCE and to 0.97 ± 0.02-fold
over control for 100 mg/kg of RCE at p < 0.01 (Fig. 3a). The
lipid oxidation marker MDA was 1.56 ± 0.29 nmol/mg pro-
tein for 50 mg/kg of RCE (p < 0.05) and 1.37 ± 0.07 nmol/
mg protein for 100 mg/kg of RCE (p < 0.01) (Fig. 3b). The
protein carbonyl oxidation protein marker was 2.42 ± 0.23
nM/mg protein at 50 mg/kg of RCE (p < 0.05) and 2.43 ±
0.07 nM/mg at 100 mg/kg of RCE (p < 0.01) (Fig. 3c). These
results indicate that RCE administration reduces hypoxia-
induced cardiac oxidative stress. Interestingly, we also ob-
served that the levels of the antioxidant enzyme SOD2
(0.67 ± 0.08-fold of the control at p < 0.05, Fig. 3d and g)
and GPx2 (0.53 ± 0.09 fold of the control at p < 0.05, Fig. 3d
and e) were significantly decreased in the hypoxia group
compared with that in normoxia. Similarly, administration
of RCE abolished the hypoxia-suppressed expressions of
SOD2 (0.94 ± 0.08 and 1.00 ± 0.03-fold over control for 50
and 100 mg/kg of RCE, p < 0.05, respectively) and GPx2
(0.90 ± 0.05 and 0.86 ± 0.05-fold over control for 50 and
100 mg/kg of RCE, p < 0.05, respectively). However, no
significant alteration of SOD1 expression exists under those
conditions.
RCE eliminates hypoxia-induced cardiac apoptosis
In order to investigate the effect of RCE on hypoxia-
induced cardiac apoptosis, the key apoptotic proteins were
examined. We showed that hypoxia significantly increased
the pro-apoptotic protein levels of cleaved caspase 3 (1.28
± 0.01-fold over control, p < 0.05, Fig. 4a and b) and Bax
Fig. 2 Effect of RCE on cardiac eNOS expression and downstream
effectors. The expression of eNOS was analyzed by western blotting (a).
The content of nitrite (c) and cGMP (d) was assayed by the commercial
kits. A quantitative analysis of eNOS expression level was conducted (b).
The results represent the mean ± SEM (n= 3). *p< 0.05 and ***p< 0.001
vs. the sample without RCE. #p< 0.05, ##p< 0.01, and ###p< 0.01 vs.
hypoxia (H)
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(2.00 ± 0.13-fold over control, p < 0.05, Fig. 4a and c) and
decreased the anti-apoptotic protein expressions of Bcl-xL
(0.48 ± 0.08-fold over control, p < 0.001, Fig. 4a and d)
and Bcl-2 (0.70 ± 0.05-fold over control, p < 0.001,
Fig. 4a and e), respectively. These results indicate hyp-
oxia causes an increase in cells undergoing apoptosis.
However, RCE treatment reversed the hypoxic effects
on these targets, including caspase 3 (1.14 ± 0.02 at
50 mg/kg of RCE and 0.99 ± 0.04-fold over control at
100 mg/kg of RCE at p < 0.05 (Fig. 4a and b), Bax (0.91 ±
0.16 and 1.06 ± 0.07-fold over control for 50 and 100 mg/
kg of RCE at p < 0.05, respectively, Fig. 4a and c), Bcl-xL
(0.95 ± 0.03 and 0.91 ± 0.04-fold over control for 50 and
100 mg/kg of RCE at p < 0.05, respectively, Fig. 4a and d),
and Bcl-2 (0.91 ± 0.04 and 0.83 ± 0.04-fold over control
for 50 and 100 mg/kg of RCE at p < 0.05, respectively,
Fig. 4a and e).
In order to further examine the mechanism of RCE in
hypoxic heart, the levels of p-AKT, p38 MAPK, and
ERK were measured. Hypoxia significantly decreased
the p-AKT expression at Thr308 (0.62 ± 0.05-fold over
control at p < 0.05, Fig. 4f and g) and Ser473 (0.73 ±
0.06-fold over control, p < 0.05 at Fig. 4f and h) as well
as p-p38 MAPK (0.65 ± 0.06-fold over control at p <
0.05, Fig. 4i and j). However, RCE significantly reversed
the expression of p-AKT at Thr308 (1.23 ± 0.04 and
1.10 ± 0.07-fold over control for 50 and 100 mg/kg of
RCE at p < 0.05, Fig. 4f and g) and Ser473 (1.42 ± 0.09
Fig. 3 Effect of RCE on cardiac oxidative stress markers. Hypoxia-induced oxidative stress markers in the heart tissues are shown as ROS intensity
(a), MDA content (b), and protein carbonyl content (c). The antioxidant system, SOD1, SOD2, and GPx2 were analyzed by western blotting (d).
The quantitative analysis of SOD1 (e), SOD2 (f), and GPx2 (g) expression levels were conducted. Results represent mean ± SEM (n = 6). *p < 0.05
vs. the sample without RCE. #p < 0.05 and ##p < 0.01 versus hypoxia (H)
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Fig. 4 Effect of RCE on apoptotic and anti-apoptotic markers in heart tissues. The representative apoptotic and anti-apoptotic proteins were analyzed
by western blotting (a). Quantitative analysis of caspase3 (b), Bax (c), Bcl-xL (d), and Bcl-2 (e) expression levels were conducted. Results represent mean
± SEM (n = 6). *p < 0.05 vs. the sample without RCE. #p < 0.05 and ##p < 0.01 versus hypoxia (H)
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and 1.21 ± 0.06-fold over control for 50 and 100 mg/kg of
RCE at p < 0.05, Fig. 4f and h) along with p-p38MAPK
(1.13 ± 0.01 and 1.02 ± 0.01-fold over control for 50 and
100 mg/kg of RCE at p < 0.05, Fig. 4i and j). These results
indicate that RCE promotes both the PI3K/AKT and
p38MAPK pathways under conditions of hypoxia. How-
ever, ERK expression did not change under our experi-
mental conditions.
Discussion
The heart is very sensitive to hypoxia due to its property of
high oxygen uptake [15]. Exposure to hypobaric hypoxia
can consequently result in exaggerated arterial hypoxemia
and lead to cardiac dysfunction including SCD [2, 19]. In
this study, we showed that RCE significantly normalized
the decrease in phosphorylation of eNOS produced by hyp-
oxia. RCE also reduced Arg-1 expression level and oxidative
stress markers in heart tissues under hypoxic conditions
and abolished hypoxia-induced cardiac apoptosis. Taken to-
gether, these findings indicate that RCE treatment exerts
cardioprotective effects in hypoxic animals by reducing
hypoxia-induced oxidative stress, repressing arginase activ-
ity, and regulation of cardiac NO metabolism (Fig. 5).
The expression of eNOS and NO production in the vas-
cular endothelium is crucial for the maintenance of vascu-
lar tone and cardiovascular physiology [20] including in the
pulmonary vasculature [10]. This pathway is an oxygen-
dependent process and limited by hypoxia. We showed that
hypoxia decreased the expression of phosphorylated eNOS
in the heart, as expected. However, this phenomenon was
reversed by RCE treatment. Furthermore, the contents of
cardiac nitrite and cGMP, which are markers of NO activity
in biological systems [4], were restored by RCE treatment.
These results indicated that RCE treatment shifted the
consumption of L-arginine from Arg-1 to eNOS, increasing
NO formation and its downstream effectors in the heart.
We also showed that RCE treatment affected upstream
eNOS regulatory signaling by enhancing the p-AKT level
under hypoxic conditions (Fig. 4f, g, and h). This is con-
sistent with the fact that eNOS activity is regulated by
protein kinase AKT in vascular endothelial cells [21] and
hypoxic lung tissues [22]. Based on these findings, RCE
may act to restore the expression of phosphorylated
eNOS via the PI3K/AKT-associated signaling pathway in
cardiomyocytes. However, this hypothesis requires fur-
ther investigation. A recent study using RNA microarray
technology showed that Rhodiola extract significantly
regulates the eNOS pathway in T98G human neuroglial
cells [23]. In our study, we demonstrated that RCE treat-
ment increased both eNOS expression and NO signaling
in hypoxic animals. These results might provide prelim-
inary evidence that RCE is able to restore eNOS signal-
ing in vitro and in vivo and that this may contribute to
its ability to limit hypoxic cardiac failure.
Hypoxia has been reported to increase the expression
and activity of cardiac arginase, which is highly correlated
with the severity of several cardiac and vascular disorders,
such as heart failure and myocardial ischemia [8]. Argi-
nase inhibition has been shown to both improve NO avail-
ability by shifting L-arginine utilization from arginase to
eNOS and to decrease oxidative stress in hypoxic heart
tissue [9]. Taken together, these observations suggest that
inhibition of arginase activity is a potential therapeutic
strategy in hypoxia-associated heart disorders.
We showed that RCE treatment significantly decreased
both the expression and activity of arginase in hypoxic
heart tissue and restored NO signaling. These findings
may indicate that RCE restored NO signaling partially
by suppression of arginase activity, which is regulated by
Fig. 5 The proposed mechanism of RCE against hypoxia-induced cardiac apoptosis
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various upstream factors including ROS, inflammatory
cytokines, and mitogen-activated protein kinase (MAPK)
pathways [8].
Until now, the exact regulatory mechanism of RCE on
arginase was unclear. It was reported previously that hyp-
oxia contributed to arginase activation induced by the
ROS burst through c-Jun and AP-1 interaction [9]. We
have shown that RCE treatment is able to attenuate ROS
intensity in both hypoxic lung [16] and heart tissues.
These results suggest that RCE could inhibit arginase ac-
tivity by limiting hypoxia-induced oxidative stress. Consid-
ering that arginase has been shown to be associated with
many other cardiac diseases such as atherosclerosis and
heart failure [8], it would be interesting to investigate the
efficacy of RCE against these disorders.
Hypoxia increased cardiac oxidative stress and resulted in
the impairment of NO signaling. Hypoxia also decreased
the bioavailability of NO by increasing NO destruction
through peroxynitrite formation as well as promoting un-
coupling of eNOS [7]. These events all contribute to the
pathological progression of cardiac failure [24].
Oxidative stress directly contributes to impaired cardiac-
muscle contraction by modifying proteins with high levels
of protein carbonyl groups [25]. In contrast, overexpression
of antioxidant enzymes can improve oxidative stress-
mediated cardiac defects [26]. In the present study, RCE
did not change the antioxidant system under normoxia.
However, in hypoxia, where SOD2 and GPx2 are decreased,
RCE treatment restored expression of these fundamental
cardiomyocyte anti-oxidant pathways [11, 27]. These results
are also consistent with the marked radical scavenging ac-
tivity of RCE reported in a previous study [28]. Together,
these results suggest that RCE could decrease hypoxia-
induced oxidative stress via the nonenzymatic pathway, but
not by directly increasing the expression of antioxidant
enzymes.
In a rodent model of exhaustive exercise, salidroside, a
major bioactive compound of RCE, exerted a cardioprotec-
tive effect via its antioxidant activity [15]. In this study, we
have shown that RCE reduces biomarkers of cardiac oxida-
tive stress (ROS, MDA, and protein carbonyl) in rat myo-
cardium. This suggests that the protective effect of RCE is
associated with its antioxidant potential. In addition, grow-
ing evidence shows that obstructive sleep apnea is associ-
ated with excessive ROS production induced by hypoxia.
These ROS directly contribute to decreased NO availability
and eNOS uncoupling [29] as well as heart problems in
the elderly [30]. It would be interesting to investigate
whether RCE has beneficial effects for those populations.
Hypoxia triggers many different signaling pathways in
the heart. Among them, MAPK pathways, such as ERK
and p38MAPK, are of importance [31, 32]. Most studies
concur that activation of p38MAPK and ERK signaling
is positive for cell survival [31]. In the present study,
RCE treatment significantly promoted the expression of
phosphorylated p38MAPK. However, no change was ob-
served in the level of p-ERK in our model. These results
indicated that RCE promotes cardiomyocyte survival
under acute hypobaric hypoxia exposure by p38MAPK,
but not ERK, signaling pathway in heart tissue. These re-
sults are similar to those observed in the acute exhaust-
ive rodent model where salidroside regulates MAPK
signaling pathways, through modification of ROS gener-
ation [15]. Thus, the regulatory effect of RCE on MAPK
pathways might again be due to the antioxidant property
of RCE.
A recent study of note showed that oxidative stress is
associated with coronary vascular tone through the
AMPK-eNOS-NO pathway. This suggests a possible role
of AMPK in the vascular endothelium under the hypoxic
condition [30]. In our previous studies, RCE regulated
both hepatic and pulmonary function via the AMPK
pathway [17, 33]. It would be interesting to clarify the
role of AMPK in hypoxia-treated animals in the future.
Myocyte apoptosis is a crucial modulator in the develop-
ment of cardiac failure [34]. Based on this idea, a growing
number of anti-apoptosis interventions for heart failure are
now under investigation. The anti-cardiac apoptotic effects
of RCE on chronic intermittent hypoxia in mice have been
recently confirmed by Lai et al. [13, 14]. In the present
study, the protective effect of RCE on acute and hypo-
baric hypoxia was investigated. We showed that RCE
not only regulated members of the Bcl-2 family (Bcl-2,
Bax, and Bcl-xL), but also the downstream markers of
apoptosis, such as caspase 3 (Fig. 4). These findings in-
dicate that RCE promotes an anti-apoptotic effect on
hypoxia-treated animals, suggesting a cardioprotective
effect of RCE for both acute and chronic hypobaric
hypoxia exposures. It should be noted that the PI3K/
AKT signaling pathway is a survival signal in response
to hypoxia [35]. Thus, the increased p-AKT level con-
ferred by RCE is consistent with the anti-apoptotic ef-
fect of RCE occurring through the activation of PI3K/
AKT signaling pathway.
In addition, there are some limitations in this study.
We did not monitor the blood pressure and heart rate
due to the limitations of a simulated hypoxia chamber.
It would be further investigated in the future study.
Conclusion
We showed that RCE decreased cardiac arginase ex-
pression, increased NO signaling, and suppressed oxi-
dative stress under hypobaric hypoxia conditions. This
was associated with reduced hypoxia-induced cardiac
apoptosis. These results might support and provide
mechanistic insight into the traditional applications of
Rhodiola crenulata for high altitude sickness.
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Additional file
Additional file 1: HPLC profiling data of salidroside (a) and RCE (b).
(DOCX 120 kb)
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